Literature DB >> 33423661

Systematic content analysis of patient evaluations of START NOW psychotherapy reveals practical strategies for improving the treatment of opioid use disorder.

Albert Yi-Que Truong1, Brian Fabian Saway1, Malek H Bouzaher1, Mustafa Nawroz Rasheed1, Sanaz Monjazeb1, Soleille Dorothy Everest1, Susan Linda Giampalmo1, David Hartman1,2, Cheryl Hartman1,2, Anita S Kablinger1,2, Robert L Trestman3,4.   

Abstract

BACKGROUND: Clinical trials provide consistent evidence for buprenorphine's efficacy in treating opioid use disorder (OUD). While the Drug Addiction Treatment Act of 2000 requires physicians to combine medication-assisted treatment (MAT) with behavioral intervention, there is no clear evidence for what form or elements of psychotherapy are most effective when coupled with MAT to treat OUD. This investigation involves focus groups designed to collect patient opinions about a specific psychotherapy, called START NOW, as well as general beliefs about various elements of psychotherapy for treating OUD. Our analysis reveals trends about patient preferences and strategies for improving OUD treatment.
METHODS: Subjects included patients enrolled in buprenorphine/naloxone MAT at our institution's office-based opioid treatment program. All subjects participated in a single START NOW group session, which was led by a provider (physician or nurse practitioner trained and standardized in delivering START NOW). Consented subjects participated in satisfaction surveys and audio-recorded focus groups assessing individual beliefs about various elements of psychotherapy for treating OUD.
RESULTS: Overall, 38 different focus groups, 92 participation events, and 44 unique subjects participated in 1-to-6 different START NOW session/audio-recorded focus group sessions led by a certified moderator. Demographic data from 36/44 subjects was collected. Seventy-five percent (33/44) completed the START NOW Assessment Protocol, which revealed self-reported behavioral trends. Analysis of all 92 START NOW Satisfaction Questionnaire results suggests that subjects' opinions about START NOW improved with increased participation. Our analysis of audio-recorded focus groups is divided into three subsections: content strategies for new psychotherapies, implementation strategies, and other observations. For example, participants request psychotherapies to target impulsivity and to teach future planning and build positive relationships.
CONCLUSIONS: The results of this study may guide implementation of psychotherapy and improve the treatment of OUD, especially as it relates to improving the modified START NOW program for treating OUD. Our study also reveals a favorable outlook of START NOW with increased participation, suggesting that any initial reticence to this program can be overcome to allow for effective implementation.

Entities:  

Keywords:  Implementation science; Medication-assisted treatment; Office-based opioid treatment; Opioid use disorder

Year:  2021        PMID: 33423661      PMCID: PMC7798217          DOI: 10.1186/s12888-020-03024-x

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  29 in total

1.  Focus group interviews part 3: analysis.

Authors:  Owen Doody; Eamonn Slevin; Laurence Taggart
Journal:  Br J Nurs       Date:  2013 Mar 14-27

2.  Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.

Authors:  Joseph Tkacz; Jamie Severt; John Cacciola; Charles Ruetsch
Journal:  Am J Addict       Date:  2011-11-18

3.  Factor structure of the Barratt impulsiveness scale.

Authors:  J H Patton; M S Stanford; E S Barratt
Journal:  J Clin Psychol       Date:  1995-11

4.  Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.

Authors:  Mark L Kraus; Daniel P Alford; Margaret M Kotz; Petros Levounis; Todd W Mandell; Marjorie Meyer; Edwin A Salsitz; Norman Wetterau; Stephen A Wyatt
Journal:  J Addict Med       Date:  2011-12       Impact factor: 3.702

5.  Leaving buprenorphine treatment: patients' reasons for cessation of care.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-10-14

6.  Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients.

Authors:  Laxmaiah Manchikanti; James Giordano; Mark V Boswell; Bert Fellows; Rajeev Manchukonda; Vidyasagar Pampati
Journal:  J Opioid Manag       Date:  2007 Mar-Apr

7.  A buprenorphine education and training program for primary care residents: implementation and evaluation.

Authors:  Hillary V Kunins; Nancy L Sohler; Angela Giovanniello; Devin Thompson; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2013       Impact factor: 3.716

8.  Factors affecting noncompliance with buprenorphine maintenance treatment.

Authors:  Ayman Fareed; Pamela Eilender; Bethany Ketchen; Ann Marie Buchanan-Cummings; Kelly Scheinberg; Kelli Crampton; Abigail Nash; Hilaire Shongo-Hiango; Karen Drexler
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

9.  Treating homeless opioid dependent patients with buprenorphine in an office-based setting.

Authors:  Daniel P Alford; Colleen T LaBelle; Jessica M Richardson; James J O'Connell; Carole A Hohl; Debbie M Cheng; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

10.  Mental Health and Psychosocial Needs of Patients Being Treated for Opioid Use Disorder in a Primary Care Residency Clinic.

Authors:  Stephanie A Hooker; Michelle D Sherman; Mary Lonergan-Cullum; Adam Sattler; Bruce S Liese; Kathryn Justesen; Tanner Nissly; Robert Levy
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.